UBS Analyzes Shaily Engineering Plastics

UBS, a major investment firm, has recently started following Shaily Engineering Plastics. They’ve given the company a “Buy” rating, meaning they think the stock will likely go up. Their target price is ₹4,000 per share – that’s a jump of about 60% from the price on Monday. This suggests UBS believes Shaily is a good investment opportunity.

Key Points

• UBS recommends buying Shaily Engineering Plastics stock.
• Target price: ₹4,000 per share – a 60% potential increase.
• Shaily is underestimated by the market.
• Strong growth potential in consumer and industrial sectors.
• Favorable trade deals could boost India’s manufacturing.
• Large healthcare market opportunity with generic GLP-1 devices.

So, why is UBS so confident about Shaily? The company is working with big brands like IKEA, P&G, and GE Appliances. This shows they can make parts for important companies around the world.

Another reason is that a deal between India and the United States could make Indian-made products cheaper than those made in other countries. This would help Shaily sell more goods overseas. Plus, Shaily is about to start working with a really big customer in the electronics and computer industry – this could bring in a lot more money.

Shaily is also getting into the world of medicines, specifically GLP-1 drugs. These drugs are used to treat diabetes, and a patent for one of them is about to expire in countries like India, Canada, and Brazil. This could open up a huge market for Shaily to make the devices that deliver these drugs.

UBS thinks Shaily could grab 50-60% of the market for these devices in those three countries. They expect Shaily’s medicine business to grow very quickly – around 96% per year for the next few years. This medicine business could make up a big chunk of Shaily’s total sales, increasing from 21% to 55%.

Shaily is working with 23-24 global medicine companies to make these devices. It’s a tough market because technology is protected by patents, there are only a few big companies making these devices, and rules and regulations are strict. That’s why it’s hard for companies to switch between suppliers.

UBS expects Shaily’s regular business (making parts for consumer goods and industry) to grow about 18% per year for the next few years. This growth depends on trade deals and better use of Shaily’s factories. They believe this can improve profits and how well Shaily uses its money.

In short, UBS sees a lot of potential growth for Shaily Engineering Plastics because of its diverse customer base, favorable market trends, and expansion into the medicine market.

“Investing wisely requires careful consideration and expert advice.”